CNS/Neurology
DiBenedetti D, Menne H, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Heithoff K, Hartry A, Oberdhan D, Wilson H, Hoffman DL, Weinberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Hauber B, Romano (DeMuro) C. Technical review of clinical outcomes assessments across the continuum of Alzheimer's disease. Neurol Ther. 2023 Apr;12(2):571-95. doi: 10.1007/s40120-023-00443-2
Hauber B, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Hartry A, Lee D, Wilson H, Hoffman DL, Weiberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Frangiosa T, Biggar V, Slota C, Romano (DeMuro) C, DiBenedetti D. Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis. Neurol Ther. 2023 Apr;12(2):505-27. doi: 10.1007/s40120-023-00445-0
INTRODUCTION: In this phase of the ongoing What Matters Most study series designed to evaluate concepts that are meaningful to people affected by Alzheimer’s disease (AD), we quantified the importance of symptoms, impacts, and outcomes of AD to people at risk for or with AD and care partners of people with AD.
Frederiksen KS, Crawford R, Hahn-Pedersen JH, Morrison R, Jeppesen R, Doward L, Weidner W. Insights from social media posts on the lived experience of alzheimer's disease. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S352. doi: 10.1016/j.jval.2023.03.2395
OBJECTIVES: To gain insights into the lived experience of Alzheimer’s Disease (AD) for persons-living-with-AD (PwADs) from the perspective of PwADs and care partners using social media (SM) data.
Forns J, Danysh H, McQuay L, Turner ME, Dempsey C, Anthony M, Layton B. Natural history of dementia-related psychosis and antipsychotic treatment patterns in older adults in the United States. Presented at the International Conference on Alzheimer's and Parkinson's Diseases 2022; March 18, 2022. Barcelona, Spain.
AIMS: To describe the natural history and antipsychotic treatment patterns of adults with dementia-related psychosis (DRP).
Blumenfeld AM, Mordin M, Kosa KM, Castro CV, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the American Academy of Neurology (AAN) 2023 Annual Meeting; April 23, 2023. Boston, MA.
Abstract not available at this time.
Forns J, Danysh HE, McQuay LJ, Turner ME, Dempsey C, Anthony MS, Demos G, Layton JB. Clinical outcomes and treatment patterns of older adults with dementia‑related psychosis by dementia type in the United States. BMC geriatr. 2022 Oct 6;22(1):784. doi: 10.1186/s12877-022-03489-3.
Razavi M, Herring W, Gillis C, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of daily transitions to later stages of AD dementia in the US. Poster presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD); December 2, 2022. San Francisco, CA.
Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I. Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S41. doi: 10.1016/j.jval.2022.09.198
OBJECTIVES: To identify evidence gaps in the literature of the burden of illness and treatment of pemphigus vulgaris (PV) and pemphigus foliaceus (PF) to support the launch of efgartigimod to treat these rare diseases.
Yang J, Masaquel C, Arvin-Berod C, Phillips G, Godar M, Desai M, Ayguasanosa J. Evidence gap analysis of the burden of illness and treatment of primary immune thrombocytopenia. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S19. doi: 10.1016/j.jval.2022.09.094
OBJECTIVES: To identify evidence gaps in the literature on the burden of illness and treatment of adult primary immune thrombocytopenia (ITP) to support the launch of efgartigimod to treat this rare disease.